Stocks · News reference
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of $(1.94) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.
8-K filing — Generate Biomedicines, Inc. (GENB)
Filed: 2026-08-26 AccNo: 0001193125-26-365556 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits